Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key issues in inhibitor management in patients with haemophilia.

Blood transfusion = Trasfusione del sangue - 1 Jan 2014

Gomez Keith, Klamroth Robert, Mahlangu Johnny, Mancuso Maria E, Mingot María E, Ozelo Margareth Castro

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation Factors
Share to Dose-Response Relationship, Immunologic
Share to Factor IX
Share to Factor VIIa

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemophilia B

Share to Immunosuppression Therapy

Share to Multicenter Studies as Topic

Share to Primary Prevention

Source

Open in PubMed Open full text

Identifiers

PMID: 24333092
DOI: 10.2450/2013.0246-12
PMCID: PMC3934290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key issues in inhibitor management in patients with haemophilia.PMID 24333092Read ↗

Why do inhibitors arise in patients with haemophilia A?Semantic proximity Read ↗

Assessing risk factors: prevention of inhibitors in haemophilia.Semantic proximity Read ↗

Inhibitors in haemophilia: pathophysiology.Semantic proximity Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?Semantic proximity Read ↗

Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit.Semantic proximity Read ↗

How do some haemophiliacs develop inhibitors?Semantic proximity Read ↗

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.Semantic proximity Read ↗

On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VIISemantic proximity Read ↗

Evolution of the Treatments for Hemophilia.Semantic proximity Read ↗

Extensive bleeding due to an inhibitor in a haemophilia A patient with a Tyr2105Cys mutation: elimination of the inhibitor with rituximab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.